Alphatec Holdings, Inc.: directors' dealings · United States · SEC (Form 4)

About Alphatec Holdings, Inc.

Alphatec Holdings, Inc. (ticker: ATEC) is a U.S.-based medical technology company listed on the Nasdaq in the United States. The group focuses on the design, development and commercialization of solutions for spine surgery. Its model is that of a spine-only platform company, combining implants, instruments, imaging and procedure-enabling technologies into a broader surgical ecosystem. For French-speaking investors, the key investment case is not commodity hardware, but a clinically driven strategy aimed at improving spinal surgery outcomes and increasing surgeon adoption over time. The company was founded in 2003 by a team of healthcare professionals with the goal of building products that help surgeons treat musculoskeletal disorders. Over time, Alphatec reshaped its portfolio and strategically exited its international distribution business in 2016, leaving the company more focused on the U.S. market. Its corporate headquarters are in Carlsbad, California, where ATEC also expanded into a new headquarters campus in 2021 to strengthen surgeon education, product development, and commercial execution. Operationally, ATEC markets a broad set of spine surgery solutions. These include posterior fixation systems, interbody devices, deformity correction products, and enabling technologies used across the surgical workflow. The company’s platform is anchored by its core surgical portfolio and by EOS imaging, which broadened ATEC’s capabilities in low-dose imaging and preoperative / intraoperative planning. This combination is important because it allows the company to address multiple steps in the spine care pathway rather than selling isolated products. From a competitive standpoint, Alphatec operates in a crowded market dominated by large orthopedic and spine-device players. Its differentiation is based on a procedural ecosystem, proprietary technology, and close engagement with surgeons and hospitals. Management also emphasizes data and informatics as part of the value proposition, aiming to improve surgical reproducibility, workflow efficiency and clinical decision-making. That said, the company still competes against much larger incumbents with broader distribution, deeper financial resources and long-established hospital relationships. Recent developments have been positive from a growth perspective. In early 2026, ATEC reported preliminary 2025 revenue of roughly $763.4 million to $764.4 million, representing about 25% year-over-year growth, and subsequently guided to approximately $882 million to $890 million of 2026 revenue depending on the release. The company also announced exclusive U.S. distribution rights for OsteoAdapt, a next-generation rhBMP-2 biologic that is still in Phase II clinical trials for spinal fusion. In addition, ATEC refinanced its existing debt through an inaugural bank facility, reducing borrowing costs and extending maturities to 2031. Overall, Alphatec remains a growth-oriented spine medtech name on the Nasdaq, with improving scale, product momentum and a stronger financial structure, but it still requires continued execution to convert clinical differentiation into sustained profitability and market share gains.